BIOMILQ leverages breakthrough mammary biotechnology to produce human milk outside of the body to nourish a world to its full potential.
We leverage our patent-pending technology to produce nutritionally equivalent breastmilk from cultured human mammary cells. With Biomilq, families can achieve the recommended six months of exclusive breastfeeding while alleviating the climate impacts of bovine-based infant formula.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 20, 2021 | Series A | $21M | 1 | — | — | Detail |